Table of Contents: CATIE News - 2001
Canadian AIDS Treatment Information Exchange
Edited by: Alan Boutilier and Sean Hosein

Table Of Contents

December
Birth defects linked to use of certain drugs during pregnancy; High-dose chemo and cell transplants for lymphoma; Antibody therapy saves woman from lymphoma-like disease
November
Trizivir approved in Canada;Caution with nelfinavir and some lipid-lowering drugs;
October
Expanded access to tenofovir; New formulation of ddI approved in Canada;
September
Andractim for HAART-associated breast enlargement; Can low-dose shark cartilage shrink KS?;
August
Doesefavirenz (Sustiva) cause breast enlargement?; Study finds women more likely to get rash with nevirapine than men; Growth hormone used to treat humps and excess fat; Immune booster used to fight drug-resistant herpes
July
Fosamax for HIV-related bone problems; Can ginseng help suppress HIV?; Pesticides found in many ginseng supplements in the U.S.;Carnitine for high triglycerides;
June
T-20: Will long-term use weaken the immune system's ability to fight HIV?;A warning about milk thistle and drug interactions; Can vitamin E help people recover from hepatitis B?;
May
Swiss research finds that switching therapy may not lower high lipid levels; Italian doctors find that HAART-users may get different infections than non-HAART-users; "Heavy" alcohol use affects the effectiveness of anti-HIV meds; Whey to go! German study finds whey protein supplement boosts antioxidants; Hearing loss may be linked to use of nukes, Spanish doctors try switching therapy from month to month, A new side effect from Kaletra?; High blood pressure with indinavir; Severe liver damage with TB drugs; Tattoos flare up from HAART;
April
Thinning bones found in HIV+ girls;
March
St. John's wort found to lower nevirapine levels; 8th Conference on Retroviruses and Opportunistic Infections; Fusion inhibitors: T-20 and T-1249; A new protease inhibitor from Bristol-Myers Squibb; Once-daily therapy - results after one year; Switching from protease inhibitors to the non-nuke efavirenz; Focus on the immune system; Wanted: meds to attack macs; Kaletra approved in Canada; Merck pushes the envelope with once-daily indinavir; Amping amprenavir with ritonavir; From grapefruit juice to ritonavir; Protease combinations -- ritonavir and indinavir one year later; Using ritonavir with indinavir in cases of virologic failure; Causes of death shift over time; Stages in HIV infection: When to start treatment?; New treatment guidelines available; I think I CAM: Use of complementary and alternative medicine by PHAs; Kaletra vs. nelfinavir; Put this in your pipe and smoke it: Medicinal marijuana study; Transplanted livers and kidneys for HIV+ people; Garlic supplements found to lower saquinavir levels; Too much iron can cause problems;
January
FDA issues warning about d4T and ddI during pregnancy; Severe nevirapine rash found more likely in women than men
Copyright / Funding / How to reach CATIE
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2001. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.